Opinion
Video
Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, from Mayo Clinic opens a conversation around CDK4/6 inhibitor prescription for patients diagnosed with early breast cancer.
Video content above is prompted by the following:
- In the adjuvant treatment of HR-positive/HER2-negative early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years.
- What factors related to the patient or disease influences your decision to prescribe a CDK4/6 inhibitor in this setting?
Related Videos
Related Content
